Compare Natera Inc. Common Stock (NTRA) vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value (VIST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value trades at $69.94 (market cap $7.63B). The key difference: Natera Inc. Common Stock is far larger — about 7.5× Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value's market cap, and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value is more actively traded (972,922 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value for 4 Days on average.
| NTRA | VIST | |
|---|---|---|
Market Cap | $57.03B | $7.63B |
Volume | 1,131,157 | 972,922 |
Sector | Health | Energy |
52-Week High | $425.64 | $79.25 |
52-Week Low | $179.42 | $35.02 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $56.18B | $10.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Vista Energy (VIST) trades at $69.02, down 0.58% on the day, with strong bullish technical signals from moving averages despite recent earnings misses. The company demonstrates robust fundamentals with 52.72% gross margins and 23.88% net income margins, supported by 32% production growth in Q2 2026. Recent news highlights Peter Thiel's $418 million investment and positive coverage from Seeking Alpha citing 70% EBITDA margins.
The outlook remains positive with 100% analyst buy ratings and $91 consensus price target representing 32% upside. Key risks include consecutive earnings misses, high debt levels, and oil price volatility. The stock offers attractive valuation at 9.08 P/E with strong operational momentum in Argentina's Vaca Muerta basin driving growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value
Vista Energy is an independent oil and gas company focused on exploration, development, and production in Latin America. Its operations are centered on the Vaca Muerta formation in Argentina.
Read more on VIST →
